Transgene Announces Financial Calendar for 2017

STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:

Transgene SA (Paris: TNG) (Euronext: TNG) today announced its financial reporting dates for 2017:

About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs, including TG4001, in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at www.transgene.fr.

Follow us on Twitter: @TransgeneSA

View source version on businesswire.com: http://www.businesswire.com/news/home/20170105005942/en/

Transgene:
Lucie Larguier, +33 (0)3 88 27 91 04
Director Corporate Communications & IR
[email protected]
or
Media contacts:
Citigate Dewe Rogerson
David Dible / Marine Perrier
+ 44 (0)20 7638 9571
[email protected]

Source: Transgene

You May Also Be Interested In

• Insurance stocks fall after Elevance Health results show margin pressure
• Elevance Health beats estimates but shares fall on margin concerns
• The Bank of New York Mellon Corporation (BNY) Tops Q2 EPS by 22c, Beats on Revenue